In the previous three years, price per employee was the top benefit consideration for employers, however this year it dropped by 22%, landing in third place.

Only 10% of organizations expect in-person work all of the time.

President Biden's recent campaign statement is backed up by research, which has consistently found that U.S. Rx prices are significantly higher, sometimes 2-4 times as high, compared with prices in other countries.

Regardless of its outcome, this class action will dramatically change pharmacy benefit management and the standard of care to which management will be held on benefit design.